AI to transform all processes in drug development by 2026, predicts CPHI Report
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Subscribe To Our Newsletter & Stay Updated